论文部分内容阅读
新世纪以来的小分子化学新药创制更加注重首创性,快速跟进的新药的空间变小,风险滞后。就新靶标研发的新药而言,呈现“数一数二,不三不四”的态势。针对新的靶标或作用机制的新药创制需要从生物学的基础研究入手,化学生物学接续,药物化学对接。研究需要宽松的自由环境,过于指令性的项目未必实现真正意义的首创。本文从几个侧面分析了当前新药创制的要点。
Since the beginning of the new century, the creation of new small-molecule chemical drugs has paid more attention to initiative and the space for new drug to follow up quickly becomes smaller and the risk lags behind. In the case of new drugs developed by new targets, the trend is “one of the best, three or four”. The development of new drugs targeting new targets or mechanisms of action requires starting with basic research in biology, chemical biology continuation, and chemical chemistry docking. Research needs a liberal, liberal environment. Projects that are too prescriptive may not be truly original. This article analyzes the main points of current new drug creation from several aspects.